FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Histidine topics
Amino Acid
Amino Acids
Genetically
Antibodies
Immunoglobulin
Polypeptide
Nucleic Acid
Pertuzumab
Trastuzumab
Mesoporous Silica
Hemoglobin
Specificity
Carrier Molecule
Blood Plasma
Recombinant

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Histidine patents



      
           
This page is updated frequently with new Histidine-related patent applications. Subscribe to the Histidine RSS feed to automatically get the update: related Histidine RSS feeds. RSS updates for this page: Histidine RSS RSS


Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same

Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same

Date/App# patent app List of recent Histidine-related patents
11/27/14
20140349327
 Method for producing fructosyl valyl histidine oxidase preparation patent thumbnailMethod for producing fructosyl valyl histidine oxidase preparation
A method for producing a fvho preparation comprising a step of allowing at least one member selected from phosphoric acid, casein peptone, d-glucosamine hydrochloride, melibiose, sorbose, lactose, fructose, melezitose, glucono-1,5-lactone, and ribitol; and a method for producing a dried fvho preparation, comprising a step of allowing bicine to coexist.. .
11/20/14
20140343499
 Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same patent thumbnailMicroneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid.
11/20/14
20140343013
 Stabalized glycosaminoglycan preparations and related methods patent thumbnailStabalized glycosaminoglycan preparations and related methods
Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain nitrogen containing polymers (e.g., polylysine, polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).
11/20/14
20140342994
 Fusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof patent thumbnailFusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof
Provided is a fusion protein comprising circularly permuted form of trail, and the fusion protein contains circularly permuted form of trail and oligopeptides located at the n-terminus and/or c-terminus of the permuted form. The oligopeptides contain a repeating sequence consisting of 3-10 histidines.
11/13/14
20140335036
 Hair care conditioning composition comprising histidine patent thumbnailHair care conditioning composition comprising histidine
A hair care composition having from about from about 0.025% to about 0.25% by weight of the composition of histidine. The hair care composition further includes a gel matrix phase.
11/06/14
20140330198
 Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same patent thumbnailMicroneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid.
11/06/14
20140329711
 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same patent thumbnailHistidine engineered light chain antibodies and genetically modified non-human animals for generating the same
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.
11/06/14
20140328737
 Cobalt extraction method patent thumbnailCobalt extraction method
The objective of the present invention is to selectively extract cobalt from an acidic solution containing a high concentration of manganese. This cobalt extraction method extracts cobalt from an acidic solution containing manganese and cobalt by subjecting the acidic solution to solvent extraction by means of a valuable metal extraction agent comprising an amide derivative represented by general formula (i).
10/09/14
20140303099
 Compositions and methods for improving cardiovascular health patent thumbnailCompositions and methods for improving cardiovascular health
Compositions and methods for improving cardiovascular health, especially in the elderly, by delivering a selection of essential amino acids selected from the group of histidine, isoleucine, leucine, valine, lysine, methionine, phenylalanine, threonine, and arginine, which may be supplemented with a low glycemic carbohydrate and/or a medium chain fatty acid.. .
09/25/14
20140287472
 Method for producing l-amino acids using bacteriua of the enterobacteriaceae family patent thumbnailMethod for producing l-amino acids using bacteriua of the enterobacteriaceae family
There is disclosed a method for producing l-amino acid, for example l-threonine, l-lysine, l-histidine, l-phenylalanine, l-arginine or l-glutamic acid, using a bacterium of the enterobacteriaceae family, wherein the bacterium has been modified to enhance an activity of d-xylose permease.. .
09/25/14
20140286969
Anti-egfr antibody drug conjugate formulations
The invention provides a stable formulation comprising an anti-egfr antibody drug conjugate (adc), including an anti-egfr antibody, e.g., antibody 1, conjugated to an auristatin, e.g., mmaf, histidine, a sugar, and a surfactant.. .
09/18/14
20140275493
Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
Antibodies are disclosed that bind to and inhibit the anti-coagulant function of tfpi and have a lower affinity for tfpi at ph 6.0 than at ph 7.4. The lower affinity at ph 6 improves circulating half-life (t½) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded.
09/18/14
20140274790
Igg-binding peptide and method for detecting and purifying igg using same
Provided is a peptide that specifically or selectively binds to human igg. This peptide comprises an amino acid sequence consisting of 13 to 17 amino acid residues and is capable of binding to human igg, wherein the amino acid sequence is represented by formula i: (x1-3)-c-(x2)-h-r-g-(xaa1)-l-v-w-c-(x1-3), wherein, x each independently represents any amino acid residue except cysteine, c represents a cysteine residue, h represents a histidine residue, r represents an arginine residue, g represents a glycine residue, xaa1 represents a glutamic acid residue or an asparagine residue, l represents a leucine residue, v represents a valine residue, and w represents a tryptophan residue..
08/21/14
20140235503
Prediction method of glomerular filtration rate from urine samples after kidney transplantation
Disclosed is a prediction method of glomerular filtration rate (gfr) from urine samples after kidney transplantation to provide an information needed for predict renal function after the transplantation, more particularly to a prediction method of glomerular filtration rate (gfr) from urine samples after kidney transplantation, which comprises detecting metabolic profiles of five biomarkers, 5a-androst-3-en-17-one (as), glycocholic acid (gc), sphingosine (sg), tryptophan (tr) and histidine (ht), from urine samples of patients. Glomerular filtration rate (gfr) after kidney transplantation can be predicted more rapidly and precisely to provide an information needed for predict renal function after the transplantation by using five metabolites as biomarkers.
08/21/14
20140234187
Valuable metal extraction agent and valuable metal extraction method using said extraction agent
The objective of the present invention is to selectively extract light rare earth metals, and by extension, europium, from an acidic solution containing a plurality of types of rare earth metal. This valuable metal extraction agent is represented by the general formula.
08/14/14
20140227728
Novel fructosyl peptidyl oxidase
In one form, a fructosyl peptidyl oxidase derived from a budding yeast phaeosphaeria nodorum for assaying a glycated protein in a sample is provided. The fructosyl peptidyl oxidase has higher activity toward fructosyl valine as well as fructosyl valyl histidine, and may be useful in assaying hba1c with higher sensitivity and specificity.
08/07/14
20140220644
Improved nitrile hydratase
Provided is an improved nitrile hydratase with improved catalytic activity. Also provided are dna for coding the improved nitrile hydratase, a recombinant vector that contains the dna, a transformant that contains the recombinant vector, nitrile hydratase acquired from a culture of the transformant, and a method for producing the nitrile hydratase.
08/07/14
20140220147
Pharmaceutical composition comprising factor vii encapsulated in micelles
The invention relates to a pharmaceutical composition comprising factor vii encapsulated in micelles formed from block copolymer molecules containing (i) a hydrophilic polymer segment consisting of a polyalkylene glycol and (ii) a hydrophobic polymer segment consisting of a polyamino acid, with said polyamino acid comprising exclusively amino acid residues selected from the group consisting of histidine, lysine, aspartic acid and glutamic acid residues, wherein a part of said amino acid residues is substituted with a hydrophobic group.. .
07/24/14
20140206533
Organic syringomycin methods and compositions
Methods and materials for producing organic syringomycin, the methods include culturing a culture of pseudomonas syringae and a growth medium including glucose, mannitol, histidine, a magnesium source, an iron source, and a buffer with a ph of from about 6.5 to 7; extracting syringomycin from the culture to yield an extract; and purifying the extract to yield syringomycin.. .
07/24/14
20140205711
Dipeptides as feed additives
The invention relates to feed additives containing dipeptides or salts thereof, in which one amino acid residue of the dipeptide is a dl-methionyl residue and the other amino acid residue of the dipeptide is an amino acid in the l-configuration selected from lysine, threonine, tryptophan, histidine, valine, leucine, isoleucine, phenylalanine, arginine, cysteine and cystine; feed mixtures containing these additives and method of producing the dipeptides.. .
07/17/14
20140199303
Stable liquid formulation of etanercept
The present invention relates to a stable liquid formulation of etanercept (recombinant p75 stnfr:fc fusion protein), and more particularly, to a liquid formulation comprising one or more stabilizers selected from the group consisting of methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in an amount sufficient to reduce by-product formation of etanercept during storage. The liquid formulation according to the present invention effectively reduces production of etanercept by-products and to stably maintain its pharmaceutical efficacies for long-term storage.
07/10/14
20140194359
Interfering rna delivery system and uses thereof
The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering rna molecule. The system can be used for delivering interfering rna molecules into a cell in vivo or in vitro.
07/03/14
20140186415
Polymer composition and polymer material
A polymer composition including a polymer having a hydroxyl group and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group. A polymer material is also provided, including a polymer composition which includes a polymer having a hydroxyl group, and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group..
06/26/14
20140179898
Mutated protein of protein a having reduced affinity in acidic region and antibody-capturing agent
A modified protein of an extracellular domain of protein a, which has the reduced ability to bind to immunoglobulin in an acidic region, compared with the wild-type extracellular domain of protein a, without impairing a selective antibody-binding activity in a neutral region. On the basis of three-dimensional structure coordinate data on a complex of the extracellular domain of protein a bound with the fc region of immunoglobulin g, the modified protein is obtained by the substitution of amino acid residues that are located within the range of 10 angstroms from the fc region and have a 20% or more ratio of exposed surface area, by histidine residues.
06/26/14
20140178460
Lyase enzymes, nucleic acids encoding them and methods for making and using them
This invention provides polypeptides having lyase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having ammonia lyase activity, e.g., phenylalanine ammonia lyase, tyrosine ammonia lyase and/or histidine ammonia lyase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides.
06/12/14
20140161723
In vivo methods of monitoring biodistribution
Functional-lipid constructs of the structure f-s-l are disclosed, wherein f comprises a tyrosine or histidine residue, s is a spacer covalently linking f to l and l is a lipid. The functional residue may be iodinated and used to radiolabel a biological entity with 1251 and the iodinated constructs are used in a non-invasive method of monitoring the distribution of a biological entity in vivo..
06/05/14
20140155449
New use of l-histidine and derivatives thereof
The present invention discloses the use of l-histidine to reduce gadolinium accumulation into target organs, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the use of l-histidine to prevent the nsf syndrome in patients with renal functionality impairment.
06/05/14
20140154752
Glycoside hydrolases having multiple hydrolase activities
Glycoside hydrolases having at least two different hydrolytic activities are provided. In one embodiment, an isolated recombinant hydrolase having at least two activities selected from a group including asparagine derivatives, glutamine derivatives, and histidine derivatives is provided.
05/29/14
20140148532
Adhesive composition
A adhesive composition that includes at least the main components of a hydrolyzable tannin and at least one cationic polymer selected from the group including (poly-)lysine, (poly-)-dl-ornithine, ε-poly-ornithine, (poly-)arginine, (poly-)glutamine, (poly-)asparagine, (poly-)histidine, (poly-)proline, putrescine, spermidine, spermine, cadaverine, agmatine, citrulline and mixtures thereof.. .
05/15/14
20140134232
Encapsulation of plasmid dna (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between dna with cationic lipid molecules and fusogenic/nls peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or nls at their one end.
05/08/14
20140127693
Fertilization prediction and promotion
The outcome of an in vitro fertilization (ivf) of a woman in terms of chances of successful pregnancy or the fertility status of a woman is predicted based on nucleotide analysis of the histidine-rich glycoprotein (hrg) gene or protein analysis of hrg. The proline isoform of hrg or an amino acid fragment thereof can further be used to increases the success of pregnancy of a woman..
05/08/14
20140127144
Flavour modifying compounds
Wherein r1 is h, or a substituted, unsubstituted, branched or unbranched c1-c5 alkyl group and, nhr2 is a residue of an amino acid, is selected from alanine (ala), cysteine (cys), aspartic acid (asp), phenylalanine (phe), glutamic acid (glu), histidine (his), isoleucine (ile), lysine (lys), leucine (leu), methionine (met), asparagines (asn), glutamine (gln), arginine (arg), serine (ser), theronine (thr), valine (val), tryptophan (trp), tyrosine(tyr) and glycine (gly), with the proviso that the compound is not n-acetyl glycine. Also disclosed are flavour compositions and consumable products containing such compounds..
04/17/14
20140106431
High fidelity thermostable ligase and uses thereof
The present invention is directed to a mutant thermostable ligase having substantially higher fidelity than either t4 ligase or thermus thermophilus ligase. The ligase of the present invention is a mutant of a wild-type thermostable ligase having a histidine adjacent a kxdg motif, where the mutant thermostable ligase has a mutation in its amino sequence where the histidine adjacent the kxdg motif in the wild-type thermostable ligase is replaced with an arginine, and wherein x is any amino acid.
04/10/14
20140099667
Bacteriorhodopsin fusion membrane protein expression system
An expression vector is disclosed, which comprises: a) a polynucleotide sequence encoding a bacteriorhodopsin or a mutant bacteriorhodopsin; b) a multiple cloning site; c) a t7 promoter, d) a polyhistidine tag; e) a first protease cleavage site; f) optionally a second protease cleavage site; and g) optionally a linker; wherein the mutant bacteriorhodopsin comprises the residue corresponding to asn94 of seq id no: 1. Also disclosed is a fusion membrane protein expression system, which comprises: a) a polynucleotide sequence encoding a mutant haloarcula marismortui bacteriorhodopsin/d94n (hmbri/d94n) or a haloquadratum walsbyi bacteriorhodopsin (hwbr); b) a target membrane protein; and c) a t7 promoter, operably linked to the mutant hmbri/d94n or hwbr and the target membrane protein.
04/03/14
20140093472
L-histidine in ophthalmic solutions
The invention relates to an aqueous ophthalmic solution comprising 0.00001 to about 10.0 percent by weight l-histidine, 0.0001 to 3.0 percent by weight hydrogen peroxide, and optionally 0.1 to 500 parts per million of a preservative that provides superior preservative efficacy especially as against fungal microbes. These solutions may be employed in various ways including cleaning contact lenses, rinsing lenses while in the eye, storing lenses and in delivering active pharmaceutical agents to the eye..
03/27/14
20140088166
Process of making and using pharmaceutical formulations of antineoplastic agents
In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, l-histidine, l-threonine, l-asparagine, l-serine, l-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.. .
03/20/14
20140082760
Non-human animals expressing ph-sensitive immunoglobulin sequences
Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more cdrs, in an n-terminal region, and or in a loop 4 region are also provided.
03/13/14
20140072622
Vaccine against streptococcus pneumoniae
The present invention relates to improved immunogenic compositions and vaccines, methods for making them and their use in medicine. In particular the invention relates to immunogenic compositions of unconjugated streptococcus pneumoniae proteins selected from: pneumolysin and member(s) of the polyhistidine triad family (e.g.
02/27/14
20140058069
Particles and other substrates useful in protein purification and other applications
The present invention generally relates to particles, including microgel particles, for purifying proteins and other species. In one aspect, the particles comprise a metal-chelating moiety, which may be distributed substantially evenly throughout the particle in certain embodiments.
02/27/14
20140057328
Yeast cell for the production of terpenes and uses thereof
The present invention relates to a yeast cell, wherein said cell comprises a functional gene coding for soluble hydroxymethylglutaryl-coenzyme-a (hmg-coa) reductase; one or more gene(s) coding for steryl acyltransferase(s) in said cell are defective or deleted; and said cell is prototrophic for at least histidine, leucine or uracil. Moreover, the present invention relates to the use of said cell for the production of one or more terpene(s).
02/20/14
20140051628
Composition for long-acting peptide analogs
The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: a-(cm)x-peptide (seq id no: 76), wherein a is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (zyhisw)p (seq id no: 50), wherein z is any amino acid residue other than histidine, his is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if a has alkyl group with 6 to 36 carbon units x is greater than 0; and cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or n-arginine or n-lysine, wherein x is an integer between 0-6 and n may be any amino acid or none.
02/13/14
20140046040
Method for selective derivatization of oligohistidine sequence of recombinant proteins
Methods and compositions for the selective derivatization of a oligohistidine-tagged recombinant protein. A modifying compound comprised of an imidazole reactive group, a linker, and a ligating group is contacted with the recombinant protein, and a cooperative bond forms between the ligating group and the oligohistidine tag in the presence of a metal cation, and a covalent bond forms between the imidazole reactive group and an imidazole ring of the oligohistidine tag followed by the concomitant separation of the imidazole reactive group from the linker.
02/13/14
20140045244
Reverse transcriptase having improved thermostability
The present invention relates to a reverse transcriptase having improved thermostability, more precisely a mutant reverse transcriptase with improved thermostability by substitution of one or more amino acids selected from the group consisting of the 63rd glutamine (q63), the 264th lysine (k264), the 295th lysine (k295), the 306th threonine (t306), the 346th glutamic acid (e346), the 408th proline (p408), the 438th histidine (h438), and the 454th asparagin (n454) of the amino acid sequence of m-mlv originated reverse transcriptase represented by seq. Id.
02/13/14
20140044778
Nanoparticles containing ph-responsive peptide
The present invention provides a nanoparticle and cell induction agent, capable of releasing a target substance in a weakly acidic ph environment. Specifically, the present invention provides a nanoparticle comprising a peptide and a particle-forming component, the particle-forming component forming a liposome or a micelle, the peptide having a sequence with 2 to 8 units starting with his (histidine) and ending with an acidic amino acid, wherein each of the units may be identical or different..
02/13/14
20140044730
Anti-pcsk9 antibodies with ph-dependent binding characteristics
The present invention provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (pcsk9) with greater affinity at neutral ph than at acidic ph. The antibodies of the invention may possess one or more amino acid changes as compared to antibodies that do not exhibit ph-dependent binding properties.
02/06/14
20140039158
Polymeric conjugates and methods of preparing the same
Methods of preparing polymer target conjugates which are substantially free of polymer attachment on the n-terminal of the targets are provided. Also provided are compositions comprising a plurality of polymer-polypeptide conjugates, said polymer-polypeptide conjugate comprising a polypeptide covalently attached to at least one polymer through an epsilon amino group of a lysine or a histidine found on the polypeptide and said conjugates containing less than 5% of the polymer-polypeptide conjugates having a polymer attached to the n-terminal of the polypeptide; and polymer target conjugates comprising a target moiety selected from the group consisting of polypeptides, proteins and the like having at least one polymer attached thereto at a site which is not the n-terminal of the target..
02/06/14
20140038856
Site-specific labeling of affinity tags in fusion proteins
The present invention provides methods and fluorescent compounds that facilitate detecting and labeling of a fusion protein by being capable of selectively binding to an affinity tag. The fluorescent compounds have the general formula a(b)n, wherein a is a fluorophore, b is a binding domain that is a charged chemical moiety, a protein or fragment thereof and n is an integer from 1-6 with the proviso that the protein or fragment thereof not be an antibody or generated from an antibody.
02/06/14
20140037574
Pharmaceutical composition
The invention provides a pharmaceutical composition for oral administration of a pharmaceutically active agent to a subject, including the pharmaceutically active agent and an inhibitor of cyp3a4. Administration of the inhibitor and the pharmaceutically active agent reduces pre-systemic degradation of the pharmaceutically active agent by cyp3a4.
01/30/14
20140031522
Novel alkali-resistant variants of protein a and their use in affinity chromatography
The present invention relates to immunoglobulin (ig)-binding proteins with alkali-resistance properties. In one embodiment, the present invention provides for a variant of an ig-binding protein, the variant comprising the ig-binding protein having at least one asparagine residue substituted with a histidine, a serine, an aspartic acid or a threonine residue.
01/09/14
20140013456
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
12/26/13
20130345284
Sirna compositions and methods for treatment of hpv and other infections
The invention provides sirna compositions that (1) interfere with viral replication of human papillomavirus (hpv), herpes simplex virus (hsv), and human immunodeficiency virus (hiv) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include sirna molecules that target hpv, complexed with a dendrimer that treats and prevents genital herpes (hsv) and hiv.
12/19/13
20130338339
Affinity chromatography matrix
The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the matrix containing the immunoglobulin containing proteins adsorbed thereon; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins.
11/14/13
20130303377
Use of single amino acids at low concentrations for influencing the life processes of crops
This invention relates to the use of a composition in low doses containing single l-amino acids, including their precursors and biologically still active metabolites, to influence the life processes of plants, such as their growth, whereby the total amount of single l-amino acids when applying the composition is at least 0.5 g/ha and at most 250 g/ha, and wherein the l-amino acids are selected from the group of glutamine, asparagine, aspartic acid, histidine, lysine, and combinations thereof with each other and/or with arginine and/or with glutamic acid.. .
10/17/13
20130273126
Tooth bleaching catalytic and application thereof
A method for forming a tooth bleaching catalytic is provided, wherein the method comprises steps as follows: firstly a plurality of histidine-functionalized mesoporous silica nano-particles (msns) is provided. Subsequently, the histidine-functionalized msns are condensating with a plurality of metal ions..
10/10/13
20130267007
Amadoriase having altered substrate specificity
This invention provides an amadoriase having high substrate specificity to fructosyl valyl histidine. Such amadoriase comprises substitution of one or more amino acid residues at positions corresponding to amino acids selected from the group consisting of position 98, position 259, position 154, position 125, position 261, position 263, position 106, position 103, position 355, position 96, position 66, position 67, position 70, position 100, position 110, position 113, position 114, and position 156 in the amadoriase derived from the genus coniochaeta.
10/03/13
20130261336
Methods and compositions for increasing the anaerobic working capacity in tissues
Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine..
10/03/13
20130260398
Phosphohistidine analogs
The present invention relates to the phosphohistidine analogs of the present invention which of the formula (i) and the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine..
09/19/13
20130247236
Non-human animals expressing ph-sensitive immunoglobulin sequences
Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more cdrs, in an n-terminal region, and or in a loop 4 region are also provided.
09/19/13
20130247235
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided.
09/19/13
20130247234
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon.
09/05/13
20130230562
Fusion protein comprising small heat shock protein, cage protein formed thereby, and novel use thereof
The present invention relates to a fusion protein comprising small heat shock protein, a cage protein formed thereby, and novel use thereof, more particularly, a fusion protein comprising a small heat shock protein, a recognition site of a protease, and a histidine polymer, wherein the recognition site and the histidine polymer are sequentially linked to a carboxyl terminal of the small heat shock protein, a cage protein formed thereby, and novel use thereof. The fusion protein of the present invention, and a cage protein formed by the self-assembly properties of the fusion protein are not cytotoxic, and emits a fluorescence signal of about 20 to about 50 times higher comparing to a single peptide for the conventional molecular imaging, per unit protein.
08/22/13
20130216532
Subcutaneous anti-her2 antibody formulations and uses thereof
The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-her2 antibody, such as e.g. Trastuzumab (herceptin™), pertuzumab or t-dm1, or a mixture of such antibody molecules for subcutaneous injection.
08/15/13
20130210023
Nucleic acid aptamers against plasmodium lactate dehydrogenase and histidine-rich protein ii and uses thereof for malaria diagnosis
The present invention provides nucleic acid aptamers that bind to plasmodium proteins lactate dehydrogenase and histidine-rich protein ii, and uses thereof for the diagnosis of malaria. Aptamers against histidine-rich protein ii may be used to detect the presence of plasmodium species in general, whereas aptamers against lactate dehydrogenase can be used to specifically detect plasmodium falciparum..
08/08/13
20130203185
Method for immobilizing a protein on self-assembled monolayer
One molecule of the amino acid selected from the five kinds of amino acids consisting of cysteine, lysine, histidine, phenylalanine, and glycine is interposed between a self-assembled monolayer and a molecule of a protein. A method for immobilizing an protein on a self-assembled monolayer includes the following steps (a) and (b) in this order: a step (a) of preparing a substrate including one molecule of an amino acid and the self-assembled monolayer and a step (b) of supplying the protein to the substrate to form a peptide bond represented by a predetermined chemical formula as a result of reaction between the carboxyl group of the one molecular of the amino acid and the amino group of the protein..
08/01/13
20130195916
System and method for identifying complex patterns of amino acids
A method and system are disclosed for identifying and/or locating complex patterns in an amino acid sequence stored in a computer file or database. According to an aspect of the present invention, techniques are provided to facilitate queries of protein databases.
07/25/13
20130189249
Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing hla to provide immunoprotection against s. Aureus pneumonia.
07/18/13
20130183350
Immunogenic compositions
This disclosure relates to immunogenic compositions comprising an isolated immunogenic s. Pneumoniae pcpa polypeptide and at least one additional antigen (such as for example, an isolated immunogenic s.
07/18/13
20130181171
Metamaterial optical elements self-assembled on protein scaffolds
Protein scaffolds from tobacco mosaic virus coat protein modified to incorporate polyhistidine can bind to a metal or a dye while having improved self-assembly characteristics. The scaffold can take the form of tubes or disks, and can further be formed into dual plasmonic ring resonators.


Popular terms: [SEARCH]

Histidine topics: Amino Acid, Amino Acids, Genetically, Antibodies, Immunoglobulin, Polypeptide, Nucleic Acid, Pertuzumab, Trastuzumab, Mesoporous Silica, Hemoglobin, Specificity, Carrier Molecule, Blood Plasma, Recombinant

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Histidine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Histidine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         



Key IP Translations - Patent Translations



0.4913

3194

0 - 1 - 71